NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma

Phase 1

Active, not recruiting

Conditions: Astrocytoma, IDH-Mutant, Grade 2
Astrocytoma, IDH-Mutant, Grade 3

Interventions: Other: Questionnaire Administration
Radiation: Radiation Therapy
Drug: Telaglenastat Hydrochloride
Drug: Temozolomide

First Posted Date: 2018-05-18

Last Posted Date: 2025-05-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 40

Registration Number: NCT03528642

Locations: 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 22 locations

Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)

Phase 2

Completed

Conditions: Advanced Malignant Solid Neoplasm
Recurrent Childhood Ependymoma
Recurrent Glioma
Recurrent Hepatoblastoma
Recurrent Malignant Germ Cell Tumor
Recurrent Medulloblastoma
Refractory Ewing Sarcoma
Refractory Glioma
Refractory Osteosarcoma
Refractory Rhabdoid Tumor

Interventions: Other: Laboratory Biomarker Analysis
Drug: Palbociclib
Other: Pharmacological Study

First Posted Date: 2018-05-16

Last Posted Date: 2024-11-01

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 23

Registration Number: NCT03526250

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Providence Alaska Medical Center, Anchorage, Alaska, United States

and more 114 locations

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Phase 4

Active, not recruiting

Conditions: Cardiovascular Diseases
Hepatitis C, Chronic
Diabetes Mellitus

Interventions: Drug: Epclusa

First Posted Date: 2018-05-11

Last Posted Date: 2025-05-28

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 121

Registration Number: NCT03520660

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Stage IV Prostate Cancer AJCC v8
Metastatic Prostate Carcinoma
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Berzosertib
Drug: Carboplatin
Drug: Docetaxel
Other: Laboratory Biomarker Analysis

First Posted Date: 2018-05-08

Last Posted Date: 2025-06-06

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 73

Registration Number: NCT03517969

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States

and more 20 locations

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

Phase 2

Completed

Conditions: Advanced Bladder Urothelial Carcinoma
Advanced Ureter Urothelial Carcinoma
Metastatic Bladder Urothelial Carcinoma
Metastatic Renal Pelvis Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Recurrent Urethral Urothelial Carcinoma
Stage III Urethral Cancer AJCC v8
Unresectable Bladder Urothelial Carcinoma
Recurrent Bladder Urothelial Carcinoma
Stage IVA Bladder Cancer AJCC v8

Interventions: Drug: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Glycosylated Recombinant Human Interleukin-7
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Procedure: Positron Emission Tomography and Computed Tomography Scan

First Posted Date: 2018-05-02

Last Posted Date: 2024-07-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 47

Registration Number: NCT03513952

Locations: 🇺🇸
FHCC South Lake Union, Seattle, Washington, United States
🇺🇸
University of Hawaii Cancer Center, Honolulu, Hawaii, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

and more 6 locations

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Phase 1

Active, not recruiting

Conditions: Lymphoma
Metastatic Malignant Solid Neoplasm
Recurrent Malignant Solid Neoplasm
Unresectable Malignant Solid Neoplasm

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Copanlisib
Procedure: Echocardiography Test
Procedure: Magnetic Resonance Imaging
Biological: Ipilimumab
Biological: Nivolumab

First Posted Date: 2018-04-19

Last Posted Date: 2025-04-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 64

Registration Number: NCT03502733

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland, United States
🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

Phase 1

Completed

Conditions: Prostate Cancer
Solid Tumor
Metastatic Prostate Cancer
Advanced Solid Tumor
Prostate Neoplasm

Interventions: Biological: M7824
Drug: N-803
Biological: MVA-BN-Brachyury
Biological: FPV-Brachyury
Drug: Epacadostat

First Posted Date: 2018-04-11

Last Posted Date: 2024-11-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 53

Registration Number: NCT03493945

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma

Phase 2

Completed

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Primary Mediastinal Large B-Cell Lymphoma

Interventions: Drug: Copanlisib Hydrochloride
Biological: Nivolumab

First Posted Date: 2018-04-02

Last Posted Date: 2025-03-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03484819

Locations: 🇺🇸
The University of Kansas Cancer Center - Olathe, Olathe, Kansas, United States
🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States

and more 12 locations

Early Tracking of Childhood Health Determinants (ETCHED) Study

Recruiting

Conditions: Diabetes Mellitus
Obesity
Fatty Liver

First Posted Date: 2018-03-29

Last Posted Date: 2025-06-05

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1500

Registration Number: NCT03481829

Locations: 🇺🇸
NIDDK, Phoenix, Phoenix, Arizona, United States

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Phase 1

Terminated

Conditions: Hepatocellular Cancer
Genitourinary Cancer
Melanoma
Colon Cancer
Gastrointestinal Cancer

Interventions: Biological: National Cancer Institute (NCI)-4650, a messenger ribonucleic acid (mRNA)-based, Personalized Cancer Vaccine

First Posted Date: 2018-03-29

Last Posted Date: 2020-06-02

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 5

Registration Number: NCT03480152

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy